Tech Company Financing Transactions
IgGenix Funding Round
IgGenix, based in San Francisco, secured $25 million from private investors, Khosla Ventures and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
7/28/2021
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
private investors (Lead Investor) (Matthias Westman)
Khosla Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further expand its discovery platform in food and nonfood allergies while accelerating its lead program into preclinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
IgGenix is a privately-held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jessica Grossman
Chief Scientific Officer
Richard Boismenu
Chief Technical Officer
Derek Croote
Browse more venture capital transactions:
Prev: 7/28/2021: Eco venture capital transaction
Next: 7/28/2021: Launchable venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs